Selective Rapalogs for mTORC1 Inhibition Without mTORC2 Toxicity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Rapamycin, despite its therapeutic potential in chronic diseases, is limited by a prohibitive safety profile that includes adverse effects such as impaired insulin sensitivity, glucose homeostasis, and lipid dysregulation due to its inhibition of mTORC2, which is uncoupled from longevity.
Innovation Solution
Development of rapamycin analogs (rapalogs) that selectively inhibit mTORC1 with minimal inhibition of mTORC2, achieved by synthesizing a library of unique rapalogs and screening for compounds with specific IC50 values, represented by structures of Formula I and Formula II, to minimize adverse effects while maintaining lifespan extension benefits.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of moving object
If rapamycin is used to inhibit mTOR signaling for lifespan extension, then longevity is improved, but adverse effects such as impaired insulin sensitivity, glucose homeostasis, and lipid dysregulation occur due to mTORC2 inhibition
Solution Approach 1:
The patent segments the mTOR complex into two distinct complexes (mTORC1 and mTORC2) and develops compounds that selectively inhibit one complex while sparing the other. By using structural modifications at specific positions (C16 and C40) of the rapamycin molecule, the invention creates selective inhibitors that target mTORC1 for lifespan extension without inhibiting mTORC2, thereby avoiding the adverse metabolic effects associated with non-selective inhibition.
Solution Approach 2:
The patent applies local quality by making specific structural modifications at particular positions (C16 and C40) of the rapamycin molecule. These localized changes in molecular structure create compounds with differentiated binding affinities for mTORC1 versus mTORC2, allowing selective inhibition of the desired target while preserving the function of the other complex.
2Duration of action of moving object
If rapamycin inhibits mTORC1 and mTORC2, then lifespan extension is achieved through mTORC1 inhibition, but chronic treatment is limited by safety concerns
Solution Approach 1:
The patent extracts the harmful effect by removing the inhibition of mTORC2 from the therapeutic action. By designing compounds that selectively inhibit mTORC1 while leaving mTORC2 unaffected, the invention separates the beneficial lifespan extension effect from the harmful metabolic side effects, thereby improving the safety profile for chronic treatment.
Solution Approach 2:
The patent changes the pharmacological parameter of selectivity by modifying the binding characteristics of rapamycin analogs. Through structural modifications at C16 and C40 positions, the compounds achieve altered affinity and selectivity parameters that favor mTORC1 inhibition over mTORC2 inhibition, enabling safe chronic treatment while maintaining lifespan extension benefits.
3Object-affected harmful factors
If selective mTORC1 inhibition is achieved through rapamycin analogs, then adverse effects are reduced, but compound complexity increases
Solution Approach 1:
The patent achieves selective inhibition through local structural modifications at specific positions (C16 and C40) of the rapamycin backbone. Rather than completely redesigning the molecule, the invention makes targeted changes at key positions that are critical for mTORC1 binding while maintaining overall molecular simplicity and avoiding excessive structural complexity.
Data Source
AI summary
Novel rapamycin analogs and uses thereof are disclosed herein. The rapamycin analogs of the present disclosure show increased mTORC1 specificity and lowered mTORC2 specificity relative to rapamycin.